Want to see SGMT full AI Analyst Report?
SGMT Stock Chart & Stats
$7.07
$0.06(0.86%)
At close: 4:00 PM EDT
$7.07
$0.06(0.86%)
Day’s Range― - ―
52-Week Range$4.50 - $11.15
Previous CloseN/A
Volume910.94K
Average Volume (3M)1.31M
Market Cap
$631.31M
Enterprise Value$172.39
Total Cash (Recent Filing)$240.13M
Total Debt (Recent Filing)$1.94M
Price to Earnings (P/E)―
Beta3.07
Next Earnings
Nov 12, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding61,591,160
10 Day Avg. Volume983,121
30 Day Avg. Volume1,309,129
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)1.72
Price to Sales (P/S)0.00
P/FCF Ratio-4.19
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.67Price Target Upside376.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Low LeverageVery low debt relative to equity and materially larger assets give Sagimet flexibility to fund trials without near-term balance-sheet strain. This cushion is valuable for a clinical-stage company whose returns depend on converting research spending into future approvals.
Extended Development RunwayThe financing materially extends development capacity, with management expecting funds to support operations through 2028, including the denifanstat Phase 3 readout. Longer runway reduces immediate dependence on additional capital while key clinical milestones are pursued.
Regulatory And Pipeline ProgressFDA clearance moves denifanstat into late-stage U.S. development and creates a clearer path toward a potential commercial product. Progress in acne, alongside the broader FASN pipeline, strengthens Sagimet’s strategic position and future revenue optionality.
Bears Say
No Meaningful Commercial RevenueSagimet has not yet demonstrated commercial scale or product revenue, leaving its business model dependent on future clinical success and regulatory approval. Until a candidate is launched, operating performance will remain structurally disconnected from commercial demand.
Persistent Cash BurnOngoing negative cash generation means Sagimet cannot currently fund operations internally and must rely on its cash balance or future financing. Although burn improved from 2025, continued trial investment will consume capital before any potential product revenue.
High Clinical Execution DependenceThe investment case remains tied to successful Phase 3 execution, regulatory approval and eventual commercialization of denifanstat. Delays, unfavorable data or approval setbacks could materially weaken the pipeline’s value because the company remains development-stage and focused on this program.
Sagimet Biosciences, Inc. Class A News
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $4.50 and its highest was $11.15 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Sagimet Biosciences, Inc. Class A’s market cap is $631.31M.
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Nov 12, 2026 which is in 79 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on Aug 11, 2026. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.251 by -$0.009.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.25.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 61,591,160 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.251. Following the earnings report the stock price went down -0.522%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Currently, no hedge funds are holding shares in SGMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sagimet Biosciences, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.67 (376.19% Upside)
$33.67 (376.19% Upside)
Blogger Sentiment
Bullish
SGMT Sentiment 86%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $578.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
91.72%
Trailing 12-Months
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences, Inc. (SGMT) is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics that target fatty acid synthase (FASN) to treat metabolic and liver-related diseases. The company’s development efforts have centered on drug candidates for conditions such as metabolic dysfunction–associated steatohepatitis (MASH/NASH), leveraging its FASN-inhibition approach to address dysregulated lipid metabolism.
SGMT Stock 12 Month Forecast
Average Price Target
$33.67
▲(376.19% Upside)
Technical Analysis
Codexis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
5.30% Insiders
6.68% Mutual Funds
39.04% Other Institutional Investors
37.05% Public Companies and
Individual Investors